Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Most people lose 1 to 2 pounds per week on semaglutide, though rates vary based on dose, duration, and individual metabolic factors. Clinical trials show average total weight loss of 10–15% over 68 weeks, but week-to-week variability is common and expected.

Weekly weight loss rates alone don't predict treatment success. Understanding what influences your personal rate—and how genetic and biomarker context can inform provider conversations—helps create realistic expectations and supports more thoughtful treatment adjustments over time.

Typical Weekly Weight Loss Ranges in Clinical Evidence

Randomized controlled trials show semaglutide users average 0.5 to 2 pounds per week during dose escalation and maintenance phases. The STEP trials (Novo Nordisk, 2021) reported average weight reductions of 10–15% at 68 weeks, translating to roughly 1–2 pounds weekly on average.

Early weeks often show steeper losses as appetite suppression takes effect and fluid balance normalizes. Mid-course plateaus are common and don't indicate treatment failure—they reflect metabolic adaptation. Consistency over months matters more than week-to-week fluctuation.

Factors That Influence Individual Weekly Weight Loss Rates

Semaglutide efficacy and weight loss rate depend on multiple factors: starting dose and titration schedule, baseline weight and metabolic rate, diet and physical activity, concurrent medications, and genetic predispositions in GLP-1 and related metabolic pathways. No two people respond identically.

Factor Impact on Weekly Weight Loss
Semaglutide Dose Higher doses (1.0–2.4 mg weekly) typically produce greater weight loss than lower doses (0.25–0.5 mg)
Baseline Body Weight People with higher starting weight often lose more total pounds weekly; percentage loss may be similar across groups
Metabolic Rate & Genetics Individual variation in GLP1R and GIPR gene expression influences appetite suppression and energy expenditure response
Diet Adherence & Activity Consistent caloric deficit and moderate exercise support and amplify semaglutide-driven weight loss
Medication Interactions Other diabetes or cardiovascular drugs may interact; thyroid function and hormonal status affect metabolism

Expected Timelines: When Weight Loss Accelerates and Plateaus

Weeks 1–4: Initial weight loss often rapid (2–3 lbs/week) due to reduced appetite and fluid shifts. Weeks 5–12: Rate typically stabilizes to 1–1.5 lbs/week as the body adjusts. Weeks 12+: Plateaus are normal as metabolic adaptation occurs; gradual continued loss is typical.

If weight loss plateaus at a maintenance dose, provider options include continuing current therapy, increasing dose under medical supervision, or adding complementary lifestyle interventions. Plateaus don't mean semaglutide has 'stopped working'—they reflect new metabolic equilibrium.

Provider-Guided Personalization and When to Reassess

Qualified healthcare providers adjust semaglutide dosing based on your individual response, tolerability, and health goals—not solely on weekly weight loss numbers. Regular check-ins help distinguish expected plateaus from true treatment inadequacy and identify side effects or medication interactions.

Before starting or adjusting semaglutide, discuss your baseline health markers, family history of metabolic conditions, and realistic weight loss goals with your provider. This conversation informs whether semaglutide aligns with your overall health plan and what weekly progress to reasonably expect.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (rs6923761), GIPR (rs1800437), and related metabolic genes (FTO rs9939609, MC4R rs17782313) that may help provide context for individual differences in appetite suppression and weight loss rate. These predispositions can support a more informed conversation with your healthcare provider about realistic expectations.

Genetic insights don't predict exact semaglutide response or guarantee specific weekly weight loss—they reveal predispositions in peptide pathways that influence how your body may respond to GLP-1 signaling. Combined with baseline metabolic markers (insulin, glucose, leptin), this data can help your provider personalize dose selection and monitoring.

Interpreting genetic findings with a qualified healthcare provider allows you to move beyond generic 'average' weight loss rates and discuss factors specific to your metabolism, genetics, and health history. This supports more thoughtful treatment planning and realistic goal-setting from the start.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves